239 related articles for article (PubMed ID: 36418292)
1. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment.
Jiang Y; Wang J; Sun M; Zuo D; Wang H; Shen J; Jiang W; Mu H; Ma X; Yin F; Lin J; Wang C; Yu S; Jiang L; Lv G; Liu F; Xue L; Tian K; Wang G; Zhou Z; Lv Y; Wang Z; Zhang T; Xu J; Yang L; Zhao K; Sun W; Tang Y; Cai Z; Wang S; Hua Y
Nat Commun; 2022 Nov; 13(1):7207. PubMed ID: 36418292
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma.
Shi D; Mu S; Pu F; Liu J; Zhong B; Hu B; Ni N; Wang H; Luu HH; Haydon RC; Shen L; Zhang Z; He TC; Shao Z
Mol Oncol; 2022 Jun; 16(11):2174-2194. PubMed ID: 34894177
[TBL] [Abstract][Full Text] [Related]
3. Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma.
Zhang HQ; Li MH; Gao P; Lan PH; Fan B; Xiao X; Lu YJ; Chen GJ; Wang Z
Orthop Surg; 2016 May; 8(2):129-38. PubMed ID: 27384721
[TBL] [Abstract][Full Text] [Related]
4. Necrotizing apoptosis-related genes prognosis and treatment effect analysis of osteosarcoma in children.
Chen Y; Wu L; Li Y; Zheng J; Zhong S; Gu S; Chen J
J Gene Med; 2024 Jan; 26(1):e3646. PubMed ID: 38100138
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA34a is associated with chemotherapy resistance, metastasis, recurrence, survival, and prognosis in patient with osteosarcoma.
Lian H; Zhou Y; Sun Z; Liu K
Medicine (Baltimore); 2022 Sep; 101(38):e30722. PubMed ID: 36197268
[TBL] [Abstract][Full Text] [Related]
6. Genomic and transcriptomic characterization of pre-operative chemotherapy response in patients with osteosarcoma.
Yang Y; Huang Z; Yuan M; Rui J; Chen R; Jin T; Sun Y; Deng Z; Shan H; Niu X; Liu W
Sci Rep; 2023 Nov; 13(1):20914. PubMed ID: 38017005
[TBL] [Abstract][Full Text] [Related]
7. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
[TBL] [Abstract][Full Text] [Related]
8. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.
Song YJ; Xu Y; Deng C; Zhu X; Fu J; Chen H; Lu J; Xu H; Song G; Tang Q; Wang J
Front Immunol; 2021; 12():623762. PubMed ID: 33959121
[TBL] [Abstract][Full Text] [Related]
9. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.
Pan R; Pan F; Zeng Z; Lei S; Yang Y; Yang Y; Hu C; Chen H; Tian X
Front Immunol; 2022; 13():1017120. PubMed ID: 36189307
[TBL] [Abstract][Full Text] [Related]
10. Signature based on metabolic-related gene pairs can predict overall survival of osteosarcoma patients.
Li LQ; Zhang LH; Yuan YB; Lu XC; Zhang Y; Liu YK; Wen J; Khader MA; Liu T; Li JZ; Zhang Y
Cancer Med; 2021 Jul; 10(13):4493-4509. PubMed ID: 34047495
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma.
Barenboim M; Kovac M; Ameline B; Jones DTW; Witt O; Bielack S; Burdach S; Baumhoer D; Nathrath M
PLoS Comput Biol; 2021 Nov; 17(11):e1009562. PubMed ID: 34762643
[TBL] [Abstract][Full Text] [Related]
12. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
Liu R; Hu Y; Liu T; Wang Y
BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489
[TBL] [Abstract][Full Text] [Related]
13. Comparative Shotgun Proteomics Reveals the Characteristic Protein Signature of Osteosarcoma Subtypes.
Alaa M; Al-Shehaby N; Anwar AM; Farid N; Shawky MS; Zamzam M; Zaky I; Elghounimy A; El-Naggar S; Magdeldin S
Cells; 2023 Aug; 12(17):. PubMed ID: 37681913
[TBL] [Abstract][Full Text] [Related]
14. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma.
Allen-Rhoades W; Kurenbekova L; Satterfield L; Parikh N; Fuja D; Shuck RL; Rainusso N; Trucco M; Barkauskas DA; Jo E; Ahern C; Hilsenbeck S; Donehower LA; Yustein JT
Cancer Med; 2015 Jul; 4(7):977-88. PubMed ID: 25784290
[TBL] [Abstract][Full Text] [Related]
15. Identification of two immune subtypes in osteosarcoma based on immune gene sets.
Yang M; Cao Y; Wang Z; Zhang T; Hua Y; Cai Z
Int Immunopharmacol; 2021 Jul; 96():107799. PubMed ID: 34162161
[TBL] [Abstract][Full Text] [Related]
16. Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma.
Wang Q; Zhang W; Guo Y; Li Y; Fu K
Aging (Albany NY); 2021 Nov; 13(21):24155-24170. PubMed ID: 34747719
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
[TBL] [Abstract][Full Text] [Related]
18. MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
Lopes LJS; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia-Filho RJ; Toledo SRC
Mol Carcinog; 2017 Jun; 56(6):1630-1641. PubMed ID: 28112450
[TBL] [Abstract][Full Text] [Related]
19. Characterizing the critical role of metabolism in osteosarcoma based on establishing novel molecular subtypes.
Zhang WB; Han FM; Liu LM; Jin HB; Yuan XY; Shang HS
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(8):2926-2943. PubMed ID: 35503637
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
